MAPT and Alzheimer disease: Indeed, treatment with the PUFA 2-hydroxydocosahexaenoic acid inhibits amyloid production, tau phosphorylation, and it induces an increase in PUFAs and the recovery of cognitive scores in a mouse model of human AD (5XFAD mice: [15]).